🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against superbug strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are escalating around the world, with figures suggesting over 82 million new cases annually. Notably increased rates are seen in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the context of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Receive Clearance

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This medication, which is additionally indicated for UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This milestone represents a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Results and Global Access

Based on data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The research included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in many developing nations.

Doctors directly involved have expressed positive views. The availability of a easy-to-administer therapy of this kind is described as a "critical tool" for public health efforts. This is deemed essential to reduce the burden of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.